MGLL and schizophrenia: This warrants follow-up studies of CHR, given the heterogeneity within CHR cohorts in transitioning to psychosis.84,85 Finally, future studies should address the potential role of FAAH inhibitors or cannabidiol on cognition in patients with schizophrenia, as the latter might have beneficial effects for FEP through FAAH modulation.86,87 Next, the mechanisms of 2-arachidonoyl glycerol (2-AG) and other endocannabinoid-metabolizing enzymes such as diacylglycerol lipase (DAGL) or monoacylglycerol lipase (MAGL) have to be more closely inspected as well.15